Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone

被引:46
作者
Sone, Saburo
Yano, Seiji
机构
[1] Univ Tokushima, Gradate Sch, Dept Internal Med & Mol Therapeut, Tokushima 7708503, Japan
[2] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9200934, Japan
关键词
lung cancer; bone metastasis; osteoclasts; molecular target therapy;
D O I
10.1007/s10555-007-9081-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone metastasis is a critical problem of lung cancer patients. Reproducible animal models of lung cancer bone metastasis, like NK-cell depleted SCID mouse model with SCB-5 cells, are useful to explore the molecular mechanism and search of molecular targets. SBC-5 cells overexpressed PTHrP and that treatment with anti-PTHrP neutralizing antibody inhibited the production of bone metastases of SBC-5 cells in the NK-cell depleted SCID mouse model, indicating the critical role of PTHrP in bone metastasis in this model. In addition, we demonstrated that several compounds, including bisphosphonates and reveromycin A, potentially suppress osteoclast-activity were beneficial for the treatments of bone metastasis. Multi-modality therapy may be necessary for further augmenting the therapeutic efficacy against lung cancer bone metastasis.
引用
收藏
页码:685 / 689
页数:5
相关论文
共 30 条
[1]  
ARGUELLO F, 1988, CANCER RES, V48, P6876
[2]  
ARGUELLO F, 1990, J NATL CANCER I, V82, P408
[3]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[4]   INHIBITION OF BONE-RESORPTION BY BISPHOSPHONATES - INTERACTIONS BETWEEN BISPHOSPHONATES, OSTEOCLASTS, AND BONE [J].
FLANAGAN, AM ;
CHAMBERS, TJ .
CALCIFIED TISSUE INTERNATIONAL, 1991, 49 (06) :407-415
[5]   Cancer and bone [J].
Guise, TA ;
Mundy, GR .
ENDOCRINE REVIEWS, 1998, 19 (01) :18-54
[6]  
Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO
[7]  
2-Y
[8]  
HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
[9]  
Herbst Roy S, 2006, Expert Opin Emerg Drugs, V11, P635, DOI 10.1517/14728214.11.4.635
[10]  
Ibrahim A, 2003, CLIN CANCER RES, V9, P2394